Literature DB >> 32775015

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) in a Thai Patient: The Classic Clinical Manifestations, Funduscopic Feature, and Brain Imaging Findings with a Novel Mutation in the SACS Gene.

Jindapa Srikajon1, Yuvadee Pitakpatapee1, Chanin Limwongse2, Niphon Chirapapaisan3, Prachaya Srivanitchapoom1.   

Abstract

Background: A 38-year-old woman was diagnosed autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) with a novel pathogenic variant in the SACS gene presented with gradually progressive spastic ataxia since the age of 2 years; then, she became wheelchair-bound at the age of 28 years. Phenomenology: The patient presented a combination of cerebellar dysfunctions e.g., gaze-evoked nystagmus, scanning speech, finger dysmetria, and wide-based gait, lower limb spasticity, and typical funduscopic examination which was a hypermyelinated nerve fibers radiating from the optic disc. Educational value: At present, ARSACS is recognized as a rare, worldwide, inherited movement disorder in which we should to aware of a diagnosis of this disorder in the patient who is presented with FXN gene negative early-onset spastic ataxia. Copyright:
© 2020 The Author(s).

Entities:  

Keywords:  ARSACS; Autosomal recessive spastic ataxia of Charlevoix-Saguenay; SACS gene; hereditary ataxia; novel mutation

Year:  2020        PMID: 32775015      PMCID: PMC7394210          DOI: 10.5334/tohm.68

Source DB:  PubMed          Journal:  Tremor Other Hyperkinet Mov (N Y)        ISSN: 2160-8288


Case summary

A 38-year-old woman presented with gradually progressive difficulty walking and frequent falls since the age of 2 years. At the age of 20 years, her gait was markedly unstable, and her speech was slurred. Finally, she became wheelchair-bound at the age of 28 years. Consanguinity was presented at the level of her paternal grandparents, but no family members were affected with neurological diseases. The ethnicity of the patient and her family were Thai. She and her family were originated from Cerebellar dysfunctions, including saccadic pursuit, hypermetric saccades, horizontal and vertical gaze-evoked nystagmus, scanning speech, finger dysmetria, and wide-based ataxic gait as well as spastic gait were presented (Video 1). Scleral telangiectasia, Kayser-Fleischer rings, oculomotor apraxia, and vertical supranuclear gaze palsy were not presented. Funduscopic examination showed hypermyelinated nerve fibers radiating from the optic disc (Figure 1A). Other neurological examination revealed normal cognitions and motor system with bilateral legs spasticity. Normal deep tendon reflexes except absent ankle reflexes with a positive Babinski sign were detected. Also, impaired proprioception of feet and ankles were presented.
Video 1

Phenomenology of the patient. (Segment 1) Saccadic pursuit, hypermetric saccades, horizontal and vertical gaze-evoked nystagmus; (Segment 2) Scanning speech, finger dysmetria; (Segment 3) Wide-based ataxic gait as well as spastic gait, and bilateral Pes cavus.

Figure 1

Funduscopic and Neuroimaging findings of the patient. (1A) Hypermyelinated nerve fibers radiating from the optic disc (black arrow); (1B) T2-weighted brain MRI showed multiple perpendicular linear hypointensities in pontine parenchyma (black arrow) and (1C) Superoanterior vermian (white arrow) and superior cerebellar peduncle (white arrow head) atrophy, as well as mild atrophy of the cervical spinal cord (black arrow with dash outline).

Phenomenology of the patient. (Segment 1) Saccadic pursuit, hypermetric saccades, horizontal and vertical gaze-evoked nystagmus; (Segment 2) Scanning speech, finger dysmetria; (Segment 3) Wide-based ataxic gait as well as spastic gait, and bilateral Pes cavus. Funduscopic and Neuroimaging findings of the patient. (1A) Hypermyelinated nerve fibers radiating from the optic disc (black arrow); (1B) T2-weighted brain MRI showed multiple perpendicular linear hypointensities in pontine parenchyma (black arrow) and (1C) Superoanterior vermian (white arrow) and superior cerebellar peduncle (white arrow head) atrophy, as well as mild atrophy of the cervical spinal cord (black arrow with dash outline). T2-weighted brain MRI showed multiple linear hypointensities in pontine parenchyma (Figure 1B). Superoanterior vermian and superior cerebellar peduncle atrophy, as well as mild atrophy of the cervical spinal cord, were shown (Figure 1C). Nerve conduction studies (NCS) showed sensorimotor demyelinating polyneuropathy. Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) was highly suspicious. Genetic testing for identifying the mutation of the SACS gene was performed by Invitae Corporation, CA, USA using a hybridization-based protocol and sequenced using illumine technology which is a target-capture exome sequencing. A homozygous, pathogenic variant, c.382_383del (p.Glu128Serfs*2), was identified in the SACS gene. The first documented case of ARSACS with a novel pathogenic mutation in Thailand was diagnosed.

Discussion

This patient is the first reported case of ARSACS in Thailand. ARSACS is a hereditary movement disorder characterized by the classic triad, including progressive early-onset cerebellar ataxia, lower limb spasticity, and peripheral polyneuropathy [1]. It has the highest prevalence in northeastern Quebec, Canada. However, ARSACS has recently been reported in many countries outside Canada, for example, Germany, Japan, Tunisia, Italy, Netherland, and Brazil [234]. Clinical variations of non-Quebec patients have been reported, such as normal funduscopic examination or normal NCS [3]. However, our patient followed the typical manifestations of Quebec’s patient even she presented a novel mutation in the SACS gene. Pontine linear hypointensities in T2W sequence is a pathognomonic finding in this disease [2]. Cervical and thoracic spinal cord thinning as in our patient is occasionally reported1; nevertheless, it has never been reported in other non-Quebec cases. We should to aware of a diagnosis of ARSACS in the patient who is presented with FXN gene negative early-onset spastic ataxia.
  4 in total

Review 1.  A novel homozygous SACS mutation identified by whole exome sequencing-genotype phenotype correlations of all published cases.

Authors:  Georgia Xiromerisiou; Katerina Dadouli; Chrysoula Marogianni; Antonios Provatas; Panagiotis Ntellas; Dimitrios Rikos; Pantelis Stathis; Despina Georgouli; Gedeon Loules; Maria Zamanakou; Georgios M Hadjigeorgiou
Journal:  J Mol Neurosci       Date:  2019-11-07       Impact factor: 3.444

2.  Autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  J P Bouchard; A Richter; J Mathieu; D Brunet; T J Hudson; K Morgan; S B Melançon
Journal:  Neuromuscul Disord       Date:  1998-10       Impact factor: 4.296

3.  Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): novel compound heterozygous mutations in the SACS gene.

Authors:  S Kamada; S Okawa; T Imota; M Sugawara; I Toyoshima
Journal:  J Neurol       Date:  2008-05-19       Impact factor: 4.849

4.  Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum.

Authors:  Matthis Synofzik; Anne S Soehn; Janina Gburek-Augustat; Julia Schicks; Kathrin N Karle; Rebecca Schüle; Tobias B Haack; Martin Schöning; Saskia Biskup; Sabine Rudnik-Schöneborn; Jan Senderek; Karl-Titus Hoffmann; Patrick MacLeod; Johannes Schwarz; Benjamin Bender; Stefan Krüger; Friedmar Kreuz; Peter Bauer; Ludger Schöls
Journal:  Orphanet J Rare Dis       Date:  2013-03-15       Impact factor: 4.123

  4 in total
  2 in total

Review 1.  Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration.

Authors:  Jaya Bagaria; Eva Bagyinszky; Seong Soo A An
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

Review 2.  Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix-Saguenay to develop patient-reported outcome.

Authors:  Marjolaine Tremblay; Laura Girard-Côté; Bernard Brais; Cynthia Gagnon
Journal:  Orphanet J Rare Dis       Date:  2022-10-01       Impact factor: 4.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.